R&D channel feed – Endpoints News

R&D channel feed

Marks’ exit at FDA rattles an already teetering biotech industry

Last month

Lilly's heart disease drug could be dosed as little as once a year, study shows

Last month

Exclusive: Transcend notches Phase 2 win to treat PTSD, invigorating budding neuroplastogen class

Last month

BiomX’s phage therapy succeeds in Phase 2 diabetic bone infection study

Last month

Vertex’s second-generation diabetes cell therapy fails early-stage study

Last month

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic

Last month

Lykos’ interim CEO is set to step down

Last month

Bluebird gets new M&A bid, seeking to top private equity offer

Last month

At long last, Novartis’ radiopharma drug Pluvicto gets an expanded label

Last month

FDA approves Sanofi's RNAi drug for hemophilia A and B

Last month

BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer

Last month

Merck KGaA pays Abbisko $85M for full commercial rights to benign tumor drug

Last month

Merck details injectable Keytruda data as it awaits autumn FDA decision

Last month

Equillium says graft-versus-host drug fails Phase 3, stock dives

Last month

Candel to focus on non-squamous lung cancer following new survival data

Last month

FDA approves first drug for Prader-Willi syndrome, to tamp down insatiable hunger symptoms

Last month

Exelixis’ primary cancer drug wins FDA approval for neuroendocrine tumors

Last month

Small biotech joins list of health companies taking a trip to Trump's Mar-a-Lago

2 months ago

J&J touts new survival data pitting lung cancer combo against AstraZeneca's rival

2 months ago

Wave strengthens case for accelerated approval, with more positive Duchenne data

2 months ago

The Endpoints Slack interview: Duke’s Pranam Chatterjee unpacks AI bio’s pretty picture fallacy

2 months ago

Epicrispr raises $68M, will start clinical trial of epigenetic editing for FSHD

2 months ago

Senate confirms Makary as FDA chief with agency cuts, return-to-office in force

2 months ago

Axsome reports Phase 3 win for Sunosi in adults with ADHD, with a high-dose caveat

2 months ago

First page Previous page 3 4 567 8 9 Next page Last page